#Izokibep
LightNews LightNews
springermedicine.com
#MedNews - Phase 2 data show that the small protein therapeutic #izokibep significantly reduces disease activity in people with active psoriatic #arthritis versus placebo.

Read the full story now 👉 buff.ly/PTs3Gew

#RheumSky #Psoriasis
Izokibep produces multiple positive effects in phase 2 psoriatic arthritis study
Phase 2 data show that the small protein therapeutic izokibep significantly reduces disease activity in people with active psoriatic arthritis versus placebo.
buff.ly
May 2, 2025 at 8:30 AM
biobonanos.bsky.social
Acelyrin had suggested last year it might seek a partner for IL-17A inhibitor izokibep, which mostly delivered disappointment rather than fulfilling high hopes. This evening, it quietly returned the program's rights to Affibody, ending their 3+ year partnership. www.sec.gov/ix?doc=/Arch...
Snip of BioCentury story from August: "Despite a positive Phase III readout for izokibep in hidradenitis suppurativa, Acelyrin Inc. (NASDAQ:SLRN) is suspending further development in the indication to extend the company’s cash runway and prioritize development of another program. The biotech said the IL-17A inhibitor met the primary endpoint of HiSCR75 with 33% of treated HS patients achieving the endpoint vs. 21% for placebo at week 12. The company said that the data support approval for the setting, but that further development will be suspended as “a program of this breadth and size is best brought to market by a larger organization.” However, the data also don’t appear to differentiate izokibep from other competitors in HS, where Bimzelx bimekizumab from UCB S.A. (Euronext:UCB) showed a 33% HiSCR75 response rate at week 16 in Phase III HS studies, and the anti-IL-17A/F inhibitor sonelokimab from MoonLake Immunotherapeutics AG (NASDAQ:MLTX) demonstrated a 43% HiSCR75 response rate at 12 weeks in the Phase II MIRA study. Acelyrin said it will reduce its workforce by 33% and prioritize completion of a Phase II study of anti-IGF1R mAb lonigutamab to treat thyroid eye disease (TED), with a Phase III study in the indication expected to start in 1Q25. The company reported a June 30, 2024, cash position of $635.2 million, which it said it now believes will fund operations until mid-2027."
January 31, 2025 at 9:59 PM
d-and-d-world.bsky.social
Affibody's izokibep shows strong long-term results in psoriatic arthritis. New 52-week data from a Phase IIb/III trial presented at the ACR conference in Chicago

#News #PsoriaticArthritis #Rheumatology #ClinicalTrials #IL17 #Izokibep #ACR2025 #MedicalResearch
Affibody’s psoriatic arthritis therapy shows long-term promise
New 52-week data for izokibep in psoriatic arthritis show sustained efficacy and a favorable safety profile.
druganddeviceworld.com
October 27, 2025 at 5:16 PM
rheumnow.bsky.social
Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep 80mg vs PBO at wk 16 (52% vs 13%; p=0.0006) w/ 40mg=48%. Other arthritis, psoriasis, enthesitis, dactylitis, QOL outcomes also improved.https://buff.ly/4UFJiSx
April 17, 2025 at 9:01 AM
rheumnow.bsky.social
Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep 80mg vs PBO at wk 16 (52% vs 13%; p=0.0006) w/ 40mg=48%. Other arthritis, psoriasis, enthesitis, dactylitis, QOL outcomes also improved.
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study - ORA - Oxford University Research Archive
Objectives: To evaluate the efficacy and safety of izokibep, a small protein therapeutic designed to inhibit interleukin-17A, in patients with active psoriatic arthritis (PsA) over 46 weeks. Methods:…
ora.ox.ac.uk
April 14, 2025 at 11:00 PM
phalguniddw.bsky.social
Affibody reports positive Phase III results for izokibep in hidradenitis suppurativa, offering new hope for patients after past trial setbacks. Results to be presented at #EADV2025/hashtag/EADV2025" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#EADV2025 in Paris.

#News #Biotech #ClinicalTrials #HidradenitisSuppurativa #Dermatology #Izokibep #Affibody #EADV2025
Affibody’s izokibep shows phase III success after past setbacks
Affibody argues that izokibep’s high-potency selectivity for IL-17A could confer an advantage over broader IL-17 blockade strategies. Image Credit: 愚木混株 Yumu/ Unsplash. Affibody has announced positive Phase III results in hidradenitis suppurativa (HS), a chronic skin condition marked by painful nodules, abscesses, and draining fistulas. The Swedish company will present 16-week data from a 258-patient global study at the European Academy of Dermatology & Venereology (EADV) Congress in Paris taking place from 17 to 20 September.
druganddeviceworld.com
September 12, 2025 at 10:18 AM
rheumatologyadv.bsky.social
From #EULAR2026 and @eular.org: #Izokibep demonstrates durable efficacy and a favorable safety profile through 52 weeks among patients with active #PsoriaticArthritis, with sustained improvements across joint, skin, and quality of life outcomes.
Izokibep Provides Sustained PsA Disease Control Through 52 Weeks
Izokibep is safe and effective for treating PsA, with improvements in disease activity and quality of life outcomes maintained through 52 weeks.
www.rheumatologyadvisor.com
June 8, 2026 at 7:18 PM
d-and-d-world.bsky.social
Affibody’s izokibep delivers positive Phase III results in hidradenitis suppurativa: 37% of patients achieved HiSCR75 at week 16 vs 20% on placebo, with strong pain and QoL improvements.

#News #EADV2025 #HS #Dermatology #ClinicalTrials #hidradenitissuppurativa
EADV 2025: Affibody’s izokibep shows strong Phase III results in HS
Phase III trial data presented at EADV 2025 highlight a 75% reduction in abscesses and inflammatory nodules with izokibep in hidradenitis suppurativa (HS).
druganddeviceworld.com
September 23, 2025 at 3:58 PM
d-and-d-world.bsky.social
Affibody reports positive Phase III results for izokibep in hidradenitis suppurativa, offering new hope for patients after past trial setbacks. Results to be presented at #EADV2025/hashtag/EADV2025" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#EADV2025 in Paris.

#News #Biotech #ClinicalTrials #HidradenitisSuppurativa #Dermatology #Izokibep #Affibody #EADV2025
Affibody’s izokibep shows phase III success after past setbacks
Affibody argues that izokibep’s high-potency selectivity for IL-17A could confer an advantage over broader IL-17 blockade strategies. Image Credit: 愚木混株 Yumu/ Unsplash. Affibody has announced positive Phase III results in hidradenitis suppurativa (HS), a chronic skin condition marked by painful nodules, abscesses, and draining fistulas. The Swedish company will present 16-week data from a 258-patient global study at the European Academy of Dermatology & Venereology (EADV) Congress in Paris taking place from 17 to 20 September.
druganddeviceworld.com
September 12, 2025 at 10:19 AM
stocktitan.net
#SLRN ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

#news #investing #stocks

https://www.stocktitan.net/news/SLRN/acelyrin-inc-announces-topline-results-from-phase-2b-3-study-of-t81g6951are3.html
ACELYRIN's Izokibep Trial Fails Primary Endpoint in Uveitis Study, Shifts Focus to Thyroid Eye Disease Program
ACELYRIN discontinues izokibep program after missing primary endpoint in uveitis trial. Company pivots to promising thyroid eye disease candidate with $562M cash runway.
www.stocktitan.net
December 10, 2024 at 9:30 PM
phalguniddw.bsky.social
Affibody's izokibep shows strong long-term results in psoriatic arthritis. New 52-week data from a Phase IIb/III trial presented at the ACR conference in Chicago

#News #PsoriaticArthritis #Rheumatology #ClinicalTrials #IL17 #Izokibep #ACR2025 #MedicalResearch
Affibody’s psoriatic arthritis therapy shows long-term promise
New 52-week data for izokibep in psoriatic arthritis show sustained efficacy and a favorable safety profile.
druganddeviceworld.com
October 27, 2025 at 5:16 PM
phalguniddw.bsky.social
Affibody’s izokibep delivers positive Phase III results in hidradenitis suppurativa: 37% of patients achieved HiSCR75 at week 16 vs 20% on placebo, with strong pain and QoL improvements.

#News #EADV2025 #HS #Dermatology #ClinicalTrials #hidradenitissuppurativa
EADV 2025: Affibody’s izokibep shows strong Phase III results in HS
Phase III trial data presented at EADV 2025 highlight a 75% reduction in abscesses and inflammatory nodules with izokibep in hidradenitis suppurativa (HS).
druganddeviceworld.com
September 23, 2025 at 3:58 PM
drtimos.bsky.social
Thoughts on this? >> Affibody regains autoimmune asset, claims ex-partner
Acelyrin unable 'to fully capitalize' on potential: Acelyrin has punted the autoimmune drug… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharma #pharmaceutical #healthcare
Affibody regains autoimmune asset, claims ex-partner Acelyrin unable 'to fully capitalize' on potential
Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August. The news led Affibody to claim its former partner “has not…
dlvr.it
February 3, 2025 at 1:00 PM
zznyiu.bsky.social
Izokibep shows moderate response, again around 13% delta mark for HiSCR75 at week 12, for #hidradenitis

Not convinced more single target biologics are what we need

#EADV2025
September 17, 2025 at 1:17 PM
zznyiu.bsky.social
Very high placebo response, as with other trials, for #Izokibep trials for #hidradenitis. Response rate looks similar to other IL-17s despite novel MOA

#EADVCongress #EADV2024
September 25, 2024 at 2:20 PM
kidneystories.bsky.social
'Uniquely structured' izokibep improves skin, disease activity in psoriatic arthritis - Healio - goo.gl/alerts/C6Vj78 #GoogleAlerts
‘Uniquely structured’ izokibep improves skin, disease activity in psoriatic arthritis
The novel interleukin-17AA targeted molecule izokibep showed ACR50 response rates of more than 50% in psoriatic arthritis at 52 weeks, according to data presented at EULAR 2026 Congress.“What I ...
goo.gl
June 17, 2026 at 9:08 PM